Student and Faculty Publications
Publication Date
6-28-2023
Journal
Cancer Letters
Abstract
In recent years, antibody-drug conjugates (ADCs) have emerged as promising anti-cancer therapeutic agents with several having already received market approval for the treatment of solid tumor and hematological malignancies. As ADC technology continues to improve and the range of indications treatable by ADCs increases, the repertoire of target antigens has expanded and will undoubtedly continue to grow. G protein-coupled receptors (GPCRs) are well-characterized therapeutic targets implicated in many human pathologies, including cancer, and represent a promising emerging target of ADCs. In this review, we will discuss the past and present therapeutic targeting of GPCRs and describe ADCs as therapeutic modalities. Moreover, we will summarize the status of existing preclinical and clinical GPCR-targeted ADCs and address the potential of GPCRs as novel targets for future ADC development.
Keywords
Humans, Immunoconjugates, Antineoplastic Agents, Neoplasms, Hematologic Neoplasms, antibody, drug conjugate, G protein-coupled receptor, linker, payload
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Neoplasms Commons, Oncology Commons
Comments
PMID: 37100113